Full-Time

Senior Category Manager

Posted on 3/18/2025

Insulet Corporation

Insulet Corporation

1,001-5,000 employees

Compensation Overview

$124.9k - $187.3k/yr

+ No Bonus + No Equity + No Benefits

Senior, Expert

Acton, MA, USA

Hybrid role; specific in-office days not mentioned.

Category
Procurement & Sourcing
Operations & Logistics
Required Skills
Sales
Marketing
Graphic Design
Requirements
  • 7-10 years of industry experience, working in procurement, sales and marketing, or professional services
  • Bachelor’s degree; MBA preferred and/or equivalent combination of education and experience
Responsibilities
  • Partner with stakeholders that need to procure outside services to plan their annual spend
  • Develop Insulet-wide and department-focused strategies to identify and procure high-value outside services
  • Lead RFP/RFQ processes and subsequent selection processes and negotiations for complex services
  • Stay abreast of developments in professional services such as brand management, advertising, graphic design, and marketing and management consulting in order to serve as a value-added partner to help internal functions procure necessary outside services
  • Develop and maintain market information about pricing and industry capabilities for categories of professional services
  • Develop standard and customized RFP/RFQ processes that drive optimal supplier selection and value from the process
  • Complete contract and pricing negotiations with suppliers
  • Lead the cross functional team that engages with suppliers on issues and continuous improvement
  • Performs other duties as required.
Desired Qualifications
  • 2+ years of consulting experience preferred
  • Experience leading multicultural teams in a global, fast-paced environment preferred
  • Team player who seeks and values diverse input to hone ideas, but who also has the experience to develop strong starting proposals
  • Ability to quickly understand the business requirements and translate these into sourcing strategies that deliver business requirements while achieving cost saving targets
  • Appreciates the value of timelines and enjoys working in the focused environment that they create
  • Values giving and receiving candid feedback
  • Flexible, experienced negotiator, with the ability to see the picture clearly from both sides and select the approach best suited to the situation at hand

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Acton, Massachusetts

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • Insulet raised $444.4M to optimize capital structure and support growth.
  • Omnipod 5's expansion into five European countries boosts international presence.
  • Winning $452M in a trade secrets trial strengthens Insulet's financial position.

What critics are saying

  • Emerging diabetes care companies may challenge Insulet's market share.
  • Technological advancements require continuous R&D investment to stay competitive.
  • Supply chain vulnerabilities in semiconductor components could disrupt production.

What makes Insulet Corporation unique

  • Insulet leads in tubeless insulin pump technology with its Omnipod brand.
  • The Omnipod 5 integrates with Dexcom G7 CGM, enhancing diabetes management.
  • Insulet's multinational RADIANT trial showcases innovation in transitioning from daily injections.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Financial Modeling Prep
Mar 28th, 2025
Insulet Corporation's Financial Efficiency in the Medical Device Industry

Insulet competes with companies like DexCom, Tandem Diabetes Care, and Masimo Corporation in the diabetes care market.

Stock Titan
Mar 18th, 2025
Insulet Secures $450M Through Senior Notes Offering: Key Details on Strategic Debt Refinancing

Insulet raises $444.4M through senior notes to refinance existing convertible debt. Strategic move positions medical device maker for future growth while optimizing capital structure.

Stock Titan
Mar 18th, 2025
From Injections to Innovation - Insulet to Present Results from a Multinational Randomized Trial of Direct Transition from Multiple Daily Injections to Omnipod(R) 5 in Adults and Children with Type 1 Diabetes

Insulet (NASDAQ: PODD) will present results from its multinational RADIANT trial at the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in March 2025.

Path8 Video
Mar 11th, 2025
Insulet product launch video

This video helped Insulet launch its new iPhone app.

Financial Modeling Prep
Mar 6th, 2025
Ubiquiti Inc. (NYSE:UI) Outshines Peers in Capital Efficiency

Ubiquiti competes with companies like Fair Isaac Corporation, Paylocity Holding Corporation, Monolithic Power Systems, EPAM Systems, and Insulet Corporation.

INACTIVE